More tools:Markets·Screener·Research·Chat

Bright Minds Biosciences Inc. Common Stock (DRUG) Financial Statements

Bright Minds Biosciences Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00Z61F382
XNAS · usd
66.91▲ 1.75 (2.69%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close65.16
Day's Range64.30 – 67.77
52-Week Range39.70 – 124.24
Volume65.0K
Avg Volume144.8K
Share Statistics
Shares Outstanding
Employees25
ExchangeXNAS
Listed2021-03-08
Share count as of September 30, 2025
Loading Income Statement…
Key questions about Bright Minds Biosciences Inc. Common Stock (DRUG)
What is Bright Minds Biosciences Inc. Common Stock's Market Cap?
Bright Minds Biosciences Inc. Common Stock's Market Cap is $510.9M, based on as-reported figures from SEC (XBRL) filings.
What is Bright Minds Biosciences Inc. Common Stock's Enterprise Value?
Bright Minds Biosciences Inc. Common Stock's Enterprise Value is $451.1M, based on as-reported figures from SEC (XBRL) filings.
What is Bright Minds Biosciences Inc. Common Stock's Net Income (TTM)?
Bright Minds Biosciences Inc. Common Stock's Net Income (TTM) is -$8.8M, based on as-reported figures from SEC (XBRL) filings.
What is Bright Minds Biosciences Inc. Common Stock's Diluted EPS (TTM)?
Bright Minds Biosciences Inc. Common Stock's Diluted EPS (TTM) is -1.16, based on as-reported figures from SEC (XBRL) filings.
What is Bright Minds Biosciences Inc. Common Stock's Net Debt?
Bright Minds Biosciences Inc. Common Stock's Net Debt is -$59.8M, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemSep 30, 2025Sep 30, 2024Sep 30, 2023Sep 30, 2022Sep 30, 2021Sep 30, 2020
EXPENSES
Consulting fees
Directors’ compensation
Foreign exchange
Marketing, advertising, and investor relations
Office and administrative
Professional fees
Regulatory and filing
Research and development
Loss before other items
Other items
Interest income
Net and comprehensive loss
Basic and diluted loss per share (in CAD per share)